Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.
The safety profile of SPINRAZA
has more than 8 years of follow-up data that is consistent with those previously reported.SPINRAZA is delivered directly to the central nervous system (CNS) where motor neuron loss begins. After 4 initial loading doses, SPINRAZA is given 3 times a year.